scispace - formally typeset
B

Bei Zhang

Researcher at University of Pittsburgh

Publications -  4
Citations -  53

Bei Zhang is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Cancer research & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 11 citations.

Papers
More filters
Journal ArticleDOI

Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer.

TL;DR: In this article, two types of polydopamine (dp)-coated nanoparticles (NPs) (N/PGEM/dp-5 and N/PGE/dp)-16) were used for effective immunochemo-photothermal therapy (PTT) to inhibit both primary tumor and distal metastatic tumor.
Journal ArticleDOI

Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages

TL;DR: Interestingly, in vivo, systemic delivery of FA-PGEM/DOX led to enhanced accumulation of the NPs in tumor and drastic reduction of tumor growth in a murine 4T1.2 breast cancer model, suggesting targeting of TAM may also contribute to the improved in vivo targeted delivery and therapeutic efficacy.
Journal ArticleDOI

Metformin-conjugated micellar system with intratumoral pH responsive de-shielding for co-delivery of doxorubicin and nucleic acid

TL;DR: In this paper, a polymetformin-based polymeric micellar carrier was developed for tumor-targeted co-delivery of DOX and nucleic acids (NA), based on a structure designed to lose the PEG shell in response to the acidic extracellular tumor environment.
Journal ArticleDOI

Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier

TL;DR: In this article , a "one stone hits two birds" nanoparticle-based strategy was designed to simultaneously activate STING innate immune response while eliminating STING-associated immune resistance for the treatment of pancreatic ductal adenocarcinoma (PDAC).